Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.125 GBX | -5.80% | -7.14% | -35.00% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company shows low valuation levels, with an enterprise value at 0.53 times its sales.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-35.00% | 5.19M | - | ||
+2.49% | 42.75B | B | ||
+47.70% | 41.61B | A | ||
+11.81% | 41.34B | B- | ||
-8.83% | 26.59B | C | ||
+7.08% | 25.49B | B- | ||
-22.76% | 18.12B | B | ||
+30.45% | 12.24B | C+ | ||
-1.92% | 11.76B | C+ | ||
+9.40% | 11B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- IXI Stock
- Ratings IXICO plc